Image-guided intra-arterial administration of antibody-releasing glial progenitors to control the HIV CNS reservoir.
图像引导动脉内注射抗体释放神经胶质祖细胞来控制 HIV 中枢神经系统储库。
基本信息
- 批准号:10512770
- 负责人:
- 金额:$ 60.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse effectsAnimal ModelAnti-Retroviral AgentsAntibodiesAntibody FormationArteriogramAstrocytesBinding SitesBiological ProductsBloodBlood - brain barrier anatomyBrainBrain imagingCardiovascular systemCellsChronicClinicalCognitiveDevelopmentDiffusionDoseDrug resistanceEngineeringEngraftmentFaceGenetic EngineeringGoalsHIVHIV Envelope Protein gp120HIV InfectionsHIV therapyHIV-associated neurocognitive disorderHumanIndividualInfectionIntra-Arterial InjectionsLeadLymphocyteMagnetic Resonance ImagingMedialMetabolicMethodologyMethodsMicrogliaModelingMoodsMorbidity - disease rateMotorMusNeurologicNeuropathogenesisOligodendrogliaPenetrationPeripheralPersonsPharmaceutical PreparationsPhenotypePlasmaPositioning AttributePositron-Emission TomographyPredispositionProductionProgenitor Cell EngraftmentPropertyReproducibilityResearchRiskSafetyTestingTherapeuticTherapeutic AgentsTimeToxic effectTranslatingTransplantationVial deviceViralViral Load resultViremiaVirusWorkantiretroviral therapybasebioluminescence imagingbrain cellbrain parenchymacerebrovascularclinical developmentcomorbiditydosageengineered stem cellsexperienceimage guidedinnovationmacrophageneuroinflammationneutralizing antibodynovelnovel strategiesnovel therapeuticspreventprogenitorresistant strainstem cell therapystem cellstooltraffickingvector
项目摘要
This proposal responds to RFA DA-22-010. Progress in the treatment of HIV is undisputed with potent
combined antiretroviral therapy (cART), allowing most individuals to live relatively healthy for decades while
receiving treatment. Although cART can maintain plasma HIV viral suppression to undetectable levels,
discontinuation of cART invariably results in a rapid rebound of plasma viremia. cART’s inability to cure HIV is
due, at least in part, to persistent HIV reservoirs, such as those in the CNS, and to the limited ability of most
ARTs to cross the blood-brain barrier. In addition, because of active infection in the brain, up to 50% of those
infected may develop a spectrum of cognitive, motor, and/or mood problems collectively known as HIV-
Associated Neurocognitive Disorder (HAND). Our long-term goal is to control HIV replication in CNS and to
treat or prevent HAND in people living with HIV (PLWH). Search for new therapeutic agents with more potency
and fewer adverse effects is underway. For example, broadly HIV-neutralizing antibodies (bNAbs) are a new
class of therapeutics recently recognized to eliminate viremia. Still, due to their large size, these biologics are
even less likely than cART to reach the brain after systemic administration. Therefore, the tools that facilitate
the effective and long-lasting administration of these potent and safe drugs to the brain are urgently needed as
they can solve the challenging problem of the brain’s HIV reservoir. The goal of this proposal is to control HIV
replication in the brain by sustained delivery of bNAbs.Therefore, this proposal is based on the premise that
the inability of cART to inhibit HIV replication in the CNS can be overcome by a complementary strategy that
provides sustained release of highly efficacious bNAbs in the brain. Accordingly, we hypothesize that
sustained release of genetically-encoded HIV bNAbs in the brain by ex vivo engineered and transplanted glial
progenitor cells (GRPs) can suppress HIV replication and decrease HIV-induced neuropathogenesis.
We assembled an interdisciplinary team with expertise in (i) modeling HIV in mice; (ii) developing HIV
bNABs; (iii) stem cell-based therapy and genetic engineering of stem cells; (iv) image-guided intraarterial
injection for global cell delivery to the brain. In our preliminary work, we have shown that intra-arterially
delivered GRPs can cross the blood-brain barrier, potentially serving as carriers for local production of HIV
bNAbs in brain parenchyma. The main advantage of using GRPs in our proposed studies is their robust
engraftment, differentiation towards oligodendrocytes and astrocytes, and persistence in the brain for months
and even years after transplantation. Thus, it will meet the need for long-lasting effects elicited by bNABs to
prevent HIV replication in the CNS and may help eradicate the CNS reservoir of HIV.
Overall, we propose an innovative cell-based strategy that addresses poor drug penetration across the
blood-brain barrier to control and eradicate the HIV reservoir in the CNS. If our project demonstrates safety
and efficacy, it could be rapidly translated into the clinical settings, profoundly impacting many PLWH.
本提案响应RFA DA-22-010。艾滋病毒治疗方面的进展是无可争议的,具有强大的效力
联合抗逆转录病毒疗法(CART),使大多数人能够相对健康地生活几十年,同时
正在接受治疗。尽管CART可以将血浆HIV病毒抑制维持在无法检测的水平,
停用CART总是会导致血浆病毒血症迅速反弹。Cart无法治愈艾滋病毒是
至少部分是由于持久的艾滋病毒宿主,如在中枢神经系统的那些,以及大多数人的能力有限
跨越血脑屏障的艺术。此外,由于大脑中的活跃感染,高达50%的
感染者可能会出现一系列认知、运动和/或情绪问题,统称为HIV-
相关神经认知障碍(手)。我们的长期目标是控制艾滋病毒在中枢神经系统的复制,并
治疗或预防艾滋病毒携带者的手牵手(PLWH)。寻找更具效力的新治疗剂
而且正在产生的不良影响也在减少。例如,广泛的艾滋病毒中和抗体(BNAbs)是一种新的
最近公认的可消除病毒血症的治疗方法。尽管如此,由于它们的体积很大,这些生物制品
在全身给药后,甚至比CART更不可能到达大脑。因此,便利的工具
这些有效和安全的药物对大脑的有效和持久的给药是迫切需要的,因为
它们可以解决大脑中艾滋病毒储存库这一具有挑战性的问题。这项提案的目标是控制艾滋病毒
通过持续递送bNAbs在大脑中复制。因此,这一提议是基于以下前提
CART无法抑制HIV在中枢神经系统的复制可以通过一种补充策略来克服,即
在大脑中持续释放高效的bNAbs。因此,我们假设
体外工程神经胶质细胞在脑内持续释放基因编码的HIV bNAbs
祖细胞(GRPs)可以抑制HIV复制,减少HIV诱导的神经病变。
我们组建了一个跨学科的团队,他们的专长是(I)在小鼠身上建立艾滋病毒模型;(Ii)开发艾滋病毒
BNAbs;(3)基于干细胞的治疗和干细胞的基因工程;(4)影像引导动脉内
注射将全球细胞输送到大脑。在我们的初步工作中,我们已经表明动脉内
运送的GRPs可以穿过血脑屏障,可能成为当地产生艾滋病毒的携带者
脑实质中的bNAbs。在我们建议的研究中使用GRP的主要优势是它们的健壮性
植入,向少突胶质细胞和星形胶质细胞分化,以及在大脑中持续数月
甚至在移植后数年。因此,它将满足bNAbs产生长期影响的需要
防止艾滋病毒在中枢神经系统复制,并可能有助于根除中枢神经系统艾滋病毒的蓄积物。
总体而言,我们提出了一种创新的基于细胞的策略,以解决药物在整个
血脑屏障,控制和根除中枢神经系统中的艾滋病毒宿主。如果我们的项目证明了安全性
它可能会迅速转化为临床环境,对许多PLWH产生深远影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alonso Heredia其他文献
Alonso Heredia的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alonso Heredia', 18)}}的其他基金
Image-guided intra-arterial administration of antibody-releasing glial progenitors to control the HIV CNS reservoir.
图像引导动脉内注射抗体释放神经胶质祖细胞来控制 HIV 中枢神经系统储库。
- 批准号:
10684314 - 财政年份:2022
- 资助金额:
$ 60.43万 - 项目类别:
Impact of concomitant chemotherapy on HIV resistance to cART and reservoir size
同步化疗对 HIV 对 cART 耐药性和储库大小的影响
- 批准号:
10321231 - 财政年份:2019
- 资助金额:
$ 60.43万 - 项目类别:
Impact of concomitant chemotherapy on HIV resistance to cART and reservoir size
同步化疗对 HIV 对 cART 耐药性和储库大小的影响
- 批准号:
10544715 - 财政年份:2019
- 资助金额:
$ 60.43万 - 项目类别:
Long-Term Inhibition of HIV transcription by targeting cellular CDK9 in vivo.
通过体内靶向细胞 CDK9 长期抑制 HIV 转录。
- 批准号:
8788234 - 财政年份:2014
- 资助金额:
$ 60.43万 - 项目类别:
Long-Term Inhibition of HIV transcription by targeting cellular CDK9 in vivo.
通过体内靶向细胞 CDK9 长期抑制 HIV 转录。
- 批准号:
8847280 - 财政年份:2014
- 资助金额:
$ 60.43万 - 项目类别:
Control of HIV drug resistance in older patients
老年患者艾滋病毒耐药性的控制
- 批准号:
7753133 - 财政年份:2009
- 资助金额:
$ 60.43万 - 项目类别:
Control of HIV drug resistance in older patients
老年患者艾滋病毒耐药性的控制
- 批准号:
7897760 - 财政年份:2009
- 资助金额:
$ 60.43万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 60.43万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 60.43万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 60.43万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 60.43万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 60.43万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 60.43万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 60.43万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 60.43万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 60.43万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 60.43万 - 项目类别:
Studentship